Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level
- PMID: 37061249
- DOI: 10.1016/j.annonc.2023.02.013
Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level
Erratum in
-
Corrigendum to "Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level": [Annals of Oncology 34 (2023) 327-332].Ann Oncol. 2023 Aug;34(8):725-726. doi: 10.1016/j.annonc.2023.05.007. Epub 2023 Jun 7. Ann Oncol. 2023. PMID: 37296057 No abstract available.
Conflict of interest statement
Disclosure LB has reported consulting fees from GenentechRegeneron, Merck, Johnson and Johnson, Daiichi Sankyo, Neuvogen, Bayer, Sanofi, ORIC, Novocure, Mirati Therapeutics, Turning Point Therapeutics, AbbVie, InterVenn Biosciences, Elevation Oncology.
Comment on
-
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.Ann Oncol. 2023 Apr;34(4):377-388. doi: 10.1016/j.annonc.2023.01.011. Epub 2023 Jan 25. Ann Oncol. 2023. PMID: 36709038
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
